Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_assertion type Assertion NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_head.
- NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_assertion description "[Since 1998, the anti-HER-2 antibody trastuzumab has been used for the treatment of patients with HER-2-positive breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_provenance.
- NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_assertion evidence source_evidence_literature NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_provenance.
- NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_assertion SIO_000772 18620996 NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_provenance.
- NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_assertion wasDerivedFrom befree-2016 NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_provenance.
- NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_assertion wasGeneratedBy ECO_0000203 NP681685.RAmMojBiq8twH9WYx9LSsaGp2pwzx8cZ7Suk8X32IfJRE130_provenance.